A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor

Michael R. Marvin, Steven K. Libutti, Mark Kayton, Janet Kao, Joanne Hayward, Tracy Grikscheit, Yan Fan, Jerold Brett, A. Weinberg, Roman Nowygrod, Paul Logerfo, Carl Feind, Kristen S. Hansen, Margaret Schwarz, David Stern, John Chabot

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Therapeutic successes following treatment of murine tumors with tumor necrosis factor-α (TNF) have not been easily applied to clinical oncology because the concentrations of TNF required in humans induces systemic toxicity. This has led us to identify mediators which could sensitize tumors to the effects of TNF, permitting administration of lower doses and possible realization of the therapeutic potential of this cytokine. Our study reports the ability of a novel cytokine, endothelial-monocyte-activating polypeptide II (EMAP II), to sensitize initially resistant murine and human tumors to TNF-induced regression employing a murine model. Recombinant (r) EMAP II was purified from Escherichia coli transformed with a plasmid expressing mature EMAP II. The B16 melanoma, raised in C57BL/6 mice, or a human fibrosarcoma (HT-1080), grown in immunocompromised mice, was injected intratumorally with either vehicle or rEMAP II/heat-treated EMAP II (50-100 μg) followed by systemic TNF/heat-treated TNF (5 μg) and assessed for tumor volume, hemorrhage, and histologic appearance. Both the B16 melanoma and the HT-1080 human fibrosarcoma underwent thrombohemorrhagic and acute inflammatory changes concomitant with regression or significantly slowed growth after administration of intratumor EMAP II followed by systemic TNF. Omission or inactivation of either cytokine abrogated this effect. These results demonstrate that local treatment of certain tumors with EMAP II results in enhanced susceptibility to TNF-mediated induction of thrombohemorrhage and regression.

Original languageEnglish (US)
Pages (from-to)248-255
Number of pages8
JournalJournal of Surgical Research
Volume63
Issue number1
DOIs
StatePublished - Jun 1996
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Cytokines
Neoplasms
Experimental Melanomas
Fibrosarcoma
Hot Temperature
Medical Oncology
Tumor Burden
Inbred C57BL Mouse
small inducible cytokine subfamily E, member 1
Plasmids
Hemorrhage
Escherichia coli
Therapeutics
Growth

ASJC Scopus subject areas

  • Surgery

Cite this

Marvin, M. R., Libutti, S. K., Kayton, M., Kao, J., Hayward, J., Grikscheit, T., ... Chabot, J. (1996). A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. Journal of Surgical Research, 63(1), 248-255. https://doi.org/10.1006/jsre.1996.0256

A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. / Marvin, Michael R.; Libutti, Steven K.; Kayton, Mark; Kao, Janet; Hayward, Joanne; Grikscheit, Tracy; Fan, Yan; Brett, Jerold; Weinberg, A.; Nowygrod, Roman; Logerfo, Paul; Feind, Carl; Hansen, Kristen S.; Schwarz, Margaret; Stern, David; Chabot, John.

In: Journal of Surgical Research, Vol. 63, No. 1, 06.1996, p. 248-255.

Research output: Contribution to journalArticle

Marvin, MR, Libutti, SK, Kayton, M, Kao, J, Hayward, J, Grikscheit, T, Fan, Y, Brett, J, Weinberg, A, Nowygrod, R, Logerfo, P, Feind, C, Hansen, KS, Schwarz, M, Stern, D & Chabot, J 1996, 'A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor', Journal of Surgical Research, vol. 63, no. 1, pp. 248-255. https://doi.org/10.1006/jsre.1996.0256
Marvin, Michael R. ; Libutti, Steven K. ; Kayton, Mark ; Kao, Janet ; Hayward, Joanne ; Grikscheit, Tracy ; Fan, Yan ; Brett, Jerold ; Weinberg, A. ; Nowygrod, Roman ; Logerfo, Paul ; Feind, Carl ; Hansen, Kristen S. ; Schwarz, Margaret ; Stern, David ; Chabot, John. / A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. In: Journal of Surgical Research. 1996 ; Vol. 63, No. 1. pp. 248-255.
@article{501f1446b37242ee88006cae6c13a52d,
title = "A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor",
abstract = "Therapeutic successes following treatment of murine tumors with tumor necrosis factor-α (TNF) have not been easily applied to clinical oncology because the concentrations of TNF required in humans induces systemic toxicity. This has led us to identify mediators which could sensitize tumors to the effects of TNF, permitting administration of lower doses and possible realization of the therapeutic potential of this cytokine. Our study reports the ability of a novel cytokine, endothelial-monocyte-activating polypeptide II (EMAP II), to sensitize initially resistant murine and human tumors to TNF-induced regression employing a murine model. Recombinant (r) EMAP II was purified from Escherichia coli transformed with a plasmid expressing mature EMAP II. The B16 melanoma, raised in C57BL/6 mice, or a human fibrosarcoma (HT-1080), grown in immunocompromised mice, was injected intratumorally with either vehicle or rEMAP II/heat-treated EMAP II (50-100 μg) followed by systemic TNF/heat-treated TNF (5 μg) and assessed for tumor volume, hemorrhage, and histologic appearance. Both the B16 melanoma and the HT-1080 human fibrosarcoma underwent thrombohemorrhagic and acute inflammatory changes concomitant with regression or significantly slowed growth after administration of intratumor EMAP II followed by systemic TNF. Omission or inactivation of either cytokine abrogated this effect. These results demonstrate that local treatment of certain tumors with EMAP II results in enhanced susceptibility to TNF-mediated induction of thrombohemorrhage and regression.",
author = "Marvin, {Michael R.} and Libutti, {Steven K.} and Mark Kayton and Janet Kao and Joanne Hayward and Tracy Grikscheit and Yan Fan and Jerold Brett and A. Weinberg and Roman Nowygrod and Paul Logerfo and Carl Feind and Hansen, {Kristen S.} and Margaret Schwarz and David Stern and John Chabot",
year = "1996",
month = "6",
doi = "10.1006/jsre.1996.0256",
language = "English (US)",
volume = "63",
pages = "248--255",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor

AU - Marvin, Michael R.

AU - Libutti, Steven K.

AU - Kayton, Mark

AU - Kao, Janet

AU - Hayward, Joanne

AU - Grikscheit, Tracy

AU - Fan, Yan

AU - Brett, Jerold

AU - Weinberg, A.

AU - Nowygrod, Roman

AU - Logerfo, Paul

AU - Feind, Carl

AU - Hansen, Kristen S.

AU - Schwarz, Margaret

AU - Stern, David

AU - Chabot, John

PY - 1996/6

Y1 - 1996/6

N2 - Therapeutic successes following treatment of murine tumors with tumor necrosis factor-α (TNF) have not been easily applied to clinical oncology because the concentrations of TNF required in humans induces systemic toxicity. This has led us to identify mediators which could sensitize tumors to the effects of TNF, permitting administration of lower doses and possible realization of the therapeutic potential of this cytokine. Our study reports the ability of a novel cytokine, endothelial-monocyte-activating polypeptide II (EMAP II), to sensitize initially resistant murine and human tumors to TNF-induced regression employing a murine model. Recombinant (r) EMAP II was purified from Escherichia coli transformed with a plasmid expressing mature EMAP II. The B16 melanoma, raised in C57BL/6 mice, or a human fibrosarcoma (HT-1080), grown in immunocompromised mice, was injected intratumorally with either vehicle or rEMAP II/heat-treated EMAP II (50-100 μg) followed by systemic TNF/heat-treated TNF (5 μg) and assessed for tumor volume, hemorrhage, and histologic appearance. Both the B16 melanoma and the HT-1080 human fibrosarcoma underwent thrombohemorrhagic and acute inflammatory changes concomitant with regression or significantly slowed growth after administration of intratumor EMAP II followed by systemic TNF. Omission or inactivation of either cytokine abrogated this effect. These results demonstrate that local treatment of certain tumors with EMAP II results in enhanced susceptibility to TNF-mediated induction of thrombohemorrhage and regression.

AB - Therapeutic successes following treatment of murine tumors with tumor necrosis factor-α (TNF) have not been easily applied to clinical oncology because the concentrations of TNF required in humans induces systemic toxicity. This has led us to identify mediators which could sensitize tumors to the effects of TNF, permitting administration of lower doses and possible realization of the therapeutic potential of this cytokine. Our study reports the ability of a novel cytokine, endothelial-monocyte-activating polypeptide II (EMAP II), to sensitize initially resistant murine and human tumors to TNF-induced regression employing a murine model. Recombinant (r) EMAP II was purified from Escherichia coli transformed with a plasmid expressing mature EMAP II. The B16 melanoma, raised in C57BL/6 mice, or a human fibrosarcoma (HT-1080), grown in immunocompromised mice, was injected intratumorally with either vehicle or rEMAP II/heat-treated EMAP II (50-100 μg) followed by systemic TNF/heat-treated TNF (5 μg) and assessed for tumor volume, hemorrhage, and histologic appearance. Both the B16 melanoma and the HT-1080 human fibrosarcoma underwent thrombohemorrhagic and acute inflammatory changes concomitant with regression or significantly slowed growth after administration of intratumor EMAP II followed by systemic TNF. Omission or inactivation of either cytokine abrogated this effect. These results demonstrate that local treatment of certain tumors with EMAP II results in enhanced susceptibility to TNF-mediated induction of thrombohemorrhage and regression.

UR - http://www.scopus.com/inward/record.url?scp=0029948526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029948526&partnerID=8YFLogxK

U2 - 10.1006/jsre.1996.0256

DO - 10.1006/jsre.1996.0256

M3 - Article

C2 - 8661206

AN - SCOPUS:0029948526

VL - 63

SP - 248

EP - 255

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -